AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA
Executive Summary
AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.
You may also be interested in...
Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.
AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA
AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.
AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA
AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.